BEF, Author at The Boomer Esiason Foundation

March 19, 2019

The Boomer Esiason Foundation has awarded $10,000 scholarships to two college freshmen with cystic fibrosis. In addition to demonstrating academic success, community involvement, financial need and compliance with CF therapies, applicants for the Exercise for Life scholarship are required to keep a running log for 12...

AbbVie and Galapagos to Co-Develop CF Therapies

by BEF

CF News, Therapies

March 19, 2019

Sep 24, 2013 SOURCE: ABBVIE NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis...

Cornerstone Therapeutics Inc. announced it is now actively marketing PERTZYE® in the US

by BEF

CF News, Therapies

March 19, 2019

SOURCE Cornerstone Therapeutics Initiates PERTZYE(R) (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis CARY, NC--(Marketwired - Jul 29, 2013) - Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for...

FDA Approves New Powder form of Novartis TOBI

by BEF

CF Community, CF News, Therapies

March 19, 2019

A dry powder form of the antibiotic TOBI - TOBI Podhaler (tobramycin inhalation powder) - used to treat lung infections caused by the bacteria Pseudomonas aeruginosa has been approved by the US Food and Drug Administration (FDA). People with CF ages six and older who have Pseudomonas aeruginosa and...

PTC Therapeutics Announces Promising Results from Phase 3 Trial of Ataluren

by BEF

CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation PTC Therapeutics Inc. recently announced results from a Phase 3 clinical trial of ataluren, a potential oral drug aimed at treating the underlying cause of cystic fibrosis. The 48-week study tested ataluren in people with CF ages six and older who have what...

Progress Made on Cayston® Supply Challenges, CFF Reports

by BEF

CF Community, CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation Gilead Sciences Inc. announced this week it has made progress resolving a shortage of its inhaled antibiotic Cayston® that began earlier this year. The company said it expects it will be able to lift the restrictions on the drug’s supply in early...

FDA Approves New Drug Application for Digestive Care’s PERTZYE

by BEF

CF News, Therapies

March 19, 2019

Digestive Care, Inc. (DCI), announced it has received U.S. Food and Drug Administration (FDA) approval of its new drug application for PERTZYE™, indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. PERTZYE is a unique pancreatic enzyme product containing bicarbonate-buffered...

Vertex Reports Promising Interim Results for Phase 2 Trial of Kalydeco and VX-809

by BEF

CF News, Therapies

March 19, 2019

Source: Cystic Fibrosis Foundation Vertex Pharmaceuticals Inc. today announced promising interim results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco™ and VX-809, a CF drug in development. The results showed a significant improvement in lung function in people with two copies of the...

PMD Healthcare Giving Away Spiro PDs for World Asthma Day

by BEF

CF Community, CF News, Therapies

March 19, 2019

PMD Healthcare is encouraging the cystic fibrosis community to enter its sweepstakes contest for a chance to win a Spiro PD -- a personal spirometer. The contest is being held to mark World Asthma Day on May 2. But since Spiro PDs are meant for patients...

FDA Approves New Enzyme Therapy for People with CF

by BEF

CF News, Therapies

March 19, 2019

Source: FDA news release Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved March 1 by the U.S. Food and Drug Administration. Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious...

Author: BEF

BEF Awards $10,000 Scholarships to Two Student-Athletes

AbbVie and Galapagos to Co-Develop CF Therapies

Cornerstone Therapeutics Inc. announced it is now actively marketing PERTZYE® in the US

FDA Approves New Powder form of Novartis TOBI

PTC Therapeutics Announces Promising Results from Phase 3 Trial of Ataluren

Progress Made on Cayston® Supply Challenges, CFF Reports

FDA Approves New Drug Application for Digestive Care’s PERTZYE

Vertex Reports Promising Interim Results for Phase 2 Trial of Kalydeco and VX-809

PMD Healthcare Giving Away Spiro PDs for World Asthma Day

FDA Approves New Enzyme Therapy for People with CF

Never miss an update. Subscribe to our emails!